Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 11:40 PM
Ignite Modification Date:
2025-12-24 @ 11:40 PM
NCT ID:
NCT01747551
Eligibility Criteria:
Inclusion Criteria:
* Confirmed adenocarcinoma of esophagus, GE junction or gastric origin
* Disease is not amenable to curative resection and is unresectable, locally advanced or metastatic
* Have not received any prior chemotherapy, investigative or biologic agents for esophagogastric cancer except in the neoadjuvant or adjuvant setting
* Any major surgery must be completed at least 4 weeks prior to study entry, minor procedures must be completed at least 2 weeks prior to study entry
* Vascular access device insertion should be performed at least 1 week prior to study entry. A central line is recommended for all participants
* Willing to use adequate contraception prior to study entry, for the duration of study participation and for 3 months after the last dose of Ziv-aflibercept/placebo
Exclusion Criteria:
* History of hypertension unless adequately controlled
* Evidence of active bleeding from primary tumor at time of study entry
* Pregnant or breastfeeding
* Squamous cell carcinoma histology
* Prior treatment for advanced or metastatic disease
* Palliative radiation to \< 25% of bone marrow must have been completed 2 weeks prior to study entry, palliative RT to \> 25% must have been completed 4 weeks prior to study entry
* Known allergy to study agents
* Known dihydropyrimidine dehydrogenase deficiency or thymidylate kinase gene polymorphism predisposing participant to 5-FU toxicity
* History of symptomatic congestive heart failure
* Clinically significant peripheral arterial disease
* Grade 2 or higher sensory or motor neuropathy
* Serious unhealed wound, ulcers or bone fractures
* History of HIV positivity or hepatitis B or C
* History of abdominal fistula, wound dehiscence, GI perforation, intra abdominal abscess, uncontrolled GI bleeding or diverticulitis that required hospitalization within 6 months of study entry
* History of arterial thrombotic events
* History of CNS hemorrhage in past 6 months
* Use of warfarin
* History of prior or synchronous malignancy except if treated with curative intent more than 3 years prior to enrollment, or adequately treated non-melanoma skin cancers, cervical carcinoma in situ or prostatic intraepithelial neoplasia without evidence of prostate cancer
* Uncontrolled non-malignant illness
* Uncontrolled psychiatric illness
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01747551
Study Brief:
Protocol Section:
NCT01747551